Literature DB >> 11406628

Nucleolytic cleavage of the mixed lineage leukemia breakpoint cluster region during apoptosis.

S P Sim1, L F Liu.   

Abstract

VP-16 (etoposide) has recently been shown to induce topoisomerase II (TOP2)-mediated DNA cleavage within the mixed lineage leukemia (MLL) breakpoint cluster region (bcr), suggesting a role of TOP2 in MLL gene rearrangement. In our current studies, we have compared the induction of DNA cleavage within the MLL bcr in different cell lines after treatment with various anticancer drugs. All anticancer drugs tested including VP-16 (a TOP2-directed drug), camptothecin (a topoisomerase I-directed drug), 5-fluorouracil and methotrexate (antimetabolites), and vinblastine (a microtubule inhibitor) induced the same site-specific cleavage within the MLL bcr. This cleavage was shown to be nuclease-mediated but not TOP2-mediated by the following observations: 1) drug-induced cleavage within the MLL bcr was not protein-linked; 2) unlike TOP2-mediated cleavage, drug-induced DNA cleavage within the MLL bcr was kinetically slow and coincided with the formation of the apoptotic nucleosomal DNA ladder; 3) drug-induced cleavage within the MLL bcr was unaffected in cells with reduced nuclear TOP2; and 4) drug-induced cleavage within the MLL bcr was abolished by the caspase inhibitor, Z-Asp(OCH(3))-Glu(OCH(3))-Val-Asp(OCH(3))-FMK. The possibility that an apoptotic nuclease may be involved in cleavage of the MLL bcr and MLL gene translocation is discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11406628     DOI: 10.1074/jbc.M103962200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

1.  Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia.

Authors:  Ashley N Mays; Neil Osheroff; Yuanyuan Xiao; Joseph L Wiemels; Carolyn A Felix; Jo Ann W Byl; Kandeepan Saravanamuttu; Andrew Peniket; Robert Corser; Cherry Chang; Christine Hoyle; Anne N Parker; Syed K Hasan; Francesco Lo-Coco; Ellen Solomon; David Grimwade
Journal:  Blood       Date:  2009-11-02       Impact factor: 22.113

2.  Base excision repair proteins couple activation-induced cytidine deaminase and endonuclease G during replication stress-induced MLL destabilization.

Authors:  B Gole; E Mian; M Rall; L Wiesmüller
Journal:  Leukemia       Date:  2017-06-19       Impact factor: 11.528

3.  Premature transcript termination, trans-splicing and DNA repair: a vicious path to cancer.

Authors:  Eric Kowarz; Jennifer Merkens; Michael Karas; Theo Dingermann; Rolf Marschalek
Journal:  Am J Blood Res       Date:  2011-04-07

4.  Endonuclease G initiates DNA rearrangements at the MLL breakpoint cluster upon replication stress.

Authors:  B Gole; C Baumann; E Mian; C I Ireno; L Wiesmüller
Journal:  Oncogene       Date:  2014-08-18       Impact factor: 9.867

5.  Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies.

Authors:  Anna M Azarova; Yi Lisa Lyu; Chao-Po Lin; Yuan-Chin Tsai; Johnson Yiu-Nam Lau; James C Wang; Leroy F Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-19       Impact factor: 11.205

Review 6.  Molecular pathogenesis of MLL-associated leukemias.

Authors:  Mariko Eguchi; Minenori Eguchi-Ishimae; Mel Greaves
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

Review 7.  Molecular biology of therapy-related leukaemias.

Authors:  Melanie Joannides; David Grimwade
Journal:  Clin Transl Oncol       Date:  2010-01       Impact factor: 3.405

Review 8.  A fate worse than death: apoptosis as an oncogenic process.

Authors:  Gabriel Ichim; Stephen W G Tait
Journal:  Nat Rev Cancer       Date:  2016-07-01       Impact factor: 60.716

9.  Poly(ADP-ribose) polymerase (PARP-1) and p53 independently function in regulating double-strand break repair in primate cells.

Authors:  Silke Süsse; Claus-Jürgen Scholz; Alexander Bürkle; Lisa Wiesmüller
Journal:  Nucleic Acids Res       Date:  2004-02-02       Impact factor: 16.971

Review 10.  Etoposide sensitivity does not predict MLL rearrangements or risk of therapy-related acute myeloid leukemia.

Authors:  J Yang; A Bogni; C Cheng; W K Bleibel; X Cai; Y Fan; W Yang; J C C Rocha; D Pei; W Liu; M E Dolan; C-H Pui; M V Relling
Journal:  Clin Pharmacol Ther       Date:  2008-05-28       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.